TGM2 and ovarian carcinoma: Proteomics analyses showed that in ovarian cancer patients, TRAIL expression was positively correlated with the expression of M1 markers (CD38 and IFI44L) while having no correlation with M2 markers (TGM2 and TREM2) at the protein level (Figure 14).